Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

被引：0

作者：

Brahmer, Julie R.

Horn, Leora

Antonia, Scott

Spigel, David R.

Gandhi, Leena

Sequist, Lecia V.

Wigginton, Jon

McDonald, Dan

Kollia, Georgia

Gupta, Ashok Kumar

Gettinger, Scott N.

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] SCRI Tennessee Oncol PLLC, Nashville, TN USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[7] Bristol Myers Squibb Co, Princeton, NJ USA

[8] Yale Univ, Sch Med, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7509

引用

页数：1

共 50 条

[21] Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).
Nishio, Makoto
Hida, Toyoaki
Nakagawa, Kazuhiko
Sakai, Hiroshi
Nogami, Naoyuki
Atagi, Shinji
Takahashi, Toshiaki
Nokihara, Hiroshi
Saka, Hideo
Takenoyama, Mitsuhiro
Fujita, Shiro
Tanaka, Hiroshi
Takeda, Koji
Satouchi, Miyako
Isobe, Hiroshi
Maemondo, Makoto
Goto, Koichi
Hirashima, Tomonori
Minato, Koichi
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[22] Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
Ramalingam, S. S.
Mazieres, J.
Planchard, D.
Stinchcombe, T. E.
Dy, G. K.
Antonia, S. J.
Horn, L.
Lena, H.
Minenza, E.
Mennecier, B.
Otterson, G. A.
Campos, L. T.
Gandara, D. R.
Levy, B. P.
Nair, S. G.
Zalcman, G.
Wolf, J.
Baudelet, C.
Lestini, B. J.
Rizvi, N. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (05): : 1266 - 1267
[23] First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
Rizvi, N. A.
Shepherd, F. A.
Antonia, S. J.
Brahmer, J. R.
Chow, L. Q.
Goldman, J.
Juergens, R.
Borghaei, H.
Ready, N. E.
Gerber, D. E.
Shen, Y.
Harbison, C.
Chen, A. C.
Gettinger, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S31
[24] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
Gettinger, Scott
Horn, Leora
Antonia, Scott J.
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Sankar, Vindira
Ahlers, Christoph M.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok
Brahmer, Julie R.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
[25] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
Wolchok, Jedd D.
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Reed, Kathleen
Burke, Matthew M.
Caldwell, Anne
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Horak, Christine E.
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok Kumar
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[26] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Gettinger, Scott N.
Horn, Leora
Gandhi, Leena
Spigel, David R.
Antonia, Scott J.
Rizvi, Naiyer A.
Powderly, John D.
Heist, Rebecca S.
Carvajal, Richard D.
Jackman, David M.
Sequist, Lecia V.
Smith, David C.
Leming, Philip
Carbone, David P.
Pinder-Schenck, Mary C.
Topalian, Suzanne L.
Hodi, F. Stephen
Sosman, Jeffrey A.
Sznol, Mario
McDermott, David F.
Pardoll, Drew M.
Sankar, Vindira
Ahlers, Christoph M.
Salvati, Mark
Wigginton, Jon M.
Hellmann, Matthew D.
Kollia, Georgia D.
Gupta, Ashok K.
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2004 - U32
[27] Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)
Gettinger, S.
Chow, L. Q.
Borghaei, H.
Shen, Y.
Harbison, C.
Chen, A. C.
Rizvi, N. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S35
[28] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).
Borghaei, Hossein
Lynch, Thomas James
Rizvi, Naiyer A.
Chow, Laura Quan Man
Reilly, Robert
Crino, Lucio
Buyse, Marc E.
Ezzeddine, Rana
Lestini, Brian Joseph
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[29] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
Antonia, Scott Joseph
Brahmer, Julie R.
Gettinger, Scott N.
Chow, Laura Quan Man
Juergens, Rosalyn A.
Shepherd, Frances A.
Laurie, Scott Andrew
Gerber, David E.
Goldman, Jonathan Wade
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Borghaei, Hossein
Rizvi, Naiyer A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
Antonia, S. J.
Brahmer, J. R.
Gettinger, S.
Chow, L. Q.
Juergens, R.
Shepherd, F. A.
Laurie, S. A.
Gerber, D. E.
Goldman, J.
Shen, Y.
Harbison, C.
Chen, A. C.
Borghaei, H.
Rizvi, N. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S2

← 1 2 3 4 5 →